Role of m6A RNA Methylation in Thyroid Cancer Cell Lines.
METTL3
RNA methylation
epitranscriptome
m6A
thyroid cancer
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
29 Sep 2022
29 Sep 2022
Historique:
received:
02
08
2022
revised:
15
09
2022
accepted:
23
09
2022
entrez:
14
10
2022
pubmed:
15
10
2022
medline:
18
10
2022
Statut:
epublish
Résumé
N6-methyladenosine (m6A) is the most abundant internal modification of RNA in eukaryotic cells, and, in recent years, it has gained increasing attention. A good amount of data support the involvement of m6A modification in tumorigenesis, tumor progression, and metastatic dissemination. However, the role of this RNA modification in thyroid cancer still remains poorly investigated. In this study, m6A-related RNA methylation profiles are compared between a normal thyroid cell line and different thyroid cancer cell lines. With this approach, it was possible to identify the different patterns of m6A modification in different thyroid cancer models. Furthermore, by silencing METTL3, which is the main player in the RNA methylation machinery, it was possible to evaluate the impact of m6A modification on gene expression in an anaplastic thyroid cancer model. This experimental approach allowed us to identify
Identifiants
pubmed: 36232810
pii: ijms231911516
doi: 10.3390/ijms231911516
pmc: PMC9569446
pii:
doi:
Substances chimiques
RNA
63231-63-0
Methyltransferases
EC 2.1.1.-
METTL3 protein, human
EC 2.1.1.62
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no competing interests.
Références
Cell Death Dis. 2018 Jan 26;9(2):124
pubmed: 29374143
J Clin Invest. 2016 Mar 1;126(3):1052-66
pubmed: 26878173
Cell Death Dis. 2022 Apr 18;13(4):358
pubmed: 35436987
Nat Protoc. 2012 Mar 01;7(3):562-78
pubmed: 22383036
Mol Cancer. 2020 May 12;19(1):88
pubmed: 32398132
Cytokine. 2019 Jun;118:35-41
pubmed: 30017390
Nucleic Acids Res. 2017 Jun 2;45(10):6051-6063
pubmed: 28334903
Oncol Lett. 2018 Jan;15(1):575-579
pubmed: 29285201
Nucleic Acids Res. 2015 Jul 1;43(W1):W566-70
pubmed: 25969447
Nat Chem Biol. 2014 Feb;10(2):93-5
pubmed: 24316715
Thyroid. 2021 Mar;31(3):337-386
pubmed: 33728999
Endocrinol Metab Clin North Am. 2019 Mar;48(1):269-284
pubmed: 30717908
Mol Ther. 2020 Feb 5;28(2):599-612
pubmed: 31839484
Nucleic Acids Res. 2019 Jul 2;47(W1):W548-W555
pubmed: 31147718
Sci Adv. 2019 Jul 03;5(7):eaax0250
pubmed: 31281898
Curr Treat Options Oncol. 2020 Aug 7;21(10):78
pubmed: 32767129
Histol Histopathol. 2021 Mar;36(3):239-248
pubmed: 33170501
Mol Ther. 2021 May 5;29(5):1821-1837
pubmed: 33484966
RNA. 1997 Nov;3(11):1233-47
pubmed: 9409616
JAMA. 2017 Apr 4;317(13):1338-1348
pubmed: 28362912
Genomics Proteomics Bioinformatics. 2017 Jun;15(3):154-163
pubmed: 28533023
Oncol Rep. 2021 Sep;46(3):
pubmed: 34318905
Nat Chem Biol. 2011 Oct 16;7(12):885-7
pubmed: 22002720
J Biol Chem. 1994 Jul 1;269(26):17697-704
pubmed: 8021282
J Mol Biol. 1977 Jun 15;113(1):165-79
pubmed: 196091
Nature. 2012 Apr 29;485(7397):201-6
pubmed: 22575960
Mol Cancer. 2019 Dec 4;18(1):176
pubmed: 31801551
Int J Mol Sci. 2018 Aug 25;19(9):
pubmed: 30149601
J Virol. 1976 Oct;20(1):45-53
pubmed: 1086370
J Clin Oncol. 2018 Jan 1;36(1):7-13
pubmed: 29072975
Front Oncol. 2021 Jan 25;10:592202
pubmed: 33569345
Nature. 2016 May 25;534(7608):575-8
pubmed: 27281194
RNA Biol. 2017 Mar 4;14(3):300-304
pubmed: 28121234
Oral Oncol. 2013 Jul;49(7):702-6
pubmed: 23583302
Nat Cell Biol. 2014 Feb;16(2):191-8
pubmed: 24394384
BMC Cancer. 2012 Sep 07;12:396
pubmed: 22958914
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
Lancet. 2016 Dec 3;388(10061):2783-2795
pubmed: 27240885
Mol Cancer. 2018 Oct 23;17(1):154
pubmed: 30352606
Sci Rep. 2019 May 14;9(1):7374
pubmed: 31089242